• SEC Filings

On January 31, 2018 (the “Closing Date”), Medizone International, Inc., a Nevada corporation (the “Company”), entered into identical securities purchase agreements (the “Securities Purchase Agreements”) with specialized investment firms L2 Capital, LLC, a Kansas limited liability company (“L2”) and SBI Investments LLC, 2014-1, a statutory series of Delaware limited liability company which is managed by New York-based Sea Otter Global Ventures, LLC (“SBI” and together with L2, collectively, the “Investors”), to which the Company issued to the Investors identical unsecured convertible promissory notes (collectively, the “Notes”) in the aggregate principal amount of $285,000. The Notes accrue interest (payable at maturity of the Notes) at a rate of 8% per annum and mature six months from the issue date. The Notes were issued with original issue discount of $17,500 and $10,000 was subtracted from the proceeds paid to Medizone to reimburse the Investors for their legal fees in connection with the preparation of the Notes and the related investment agreements. Accordingly, the net proceeds received by Medizone for each Note was $125,000. The Notes are convertible at any time at the option of the Investors into shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a conversion price of $0.05 per share, which conversion price is subject to adjustment upon the occurrence of certain events of default with respect to the Notes. The Company may prepay the amount outstanding under either Note at any time by making a payment to the holder of an amount in cash equal to 130% multiplied by the total outstanding amount owed under the Note at such time of repayment. The Investor may convert the Note in whole or in part at any time after it has been called for redemption.

In connection with the issuance of the Notes, each Investor also received a warrant (collectively, the “Warrants”) to purchase 2,833,168 shares of Common Stock. The Warrants are immediately exercisable and may be exercised at any time prior to 5:00 p.m. Eastern Standard Time on the date that is the five-year anniversary of their issuance. The exercise price per share of the Warrants is equal to 110% multiplied by the closing bid price of the Common Stock on the issuance date, which was $0.0379 per share. The Warrants include a cashless net exercise provision whereby the holder can elect to receive shares equal to the value of the Warrants minus the fair market value of shares being surrendered to pay for the exercise. The Warrants contain customary anti-dilution provisions.

Also on the Closing Date, the Company entered into that certain Equity Purchase Agreement with the Investors (the “Purchase Agreement”), to which Investors committed to purchase (the “Financing”) in the aggregate, up to $10,000,000 of value of the Company’s Common Stock. On the Closing Date, the Company issued 4,087,193 shares of Common Stock (the “Commitment Shares”) to each Investor as a commitment fee with respect to the Financing. The Commitment Shares were earned in full upon the execution of the Purchase Agreement, and the ownership of the Commitment Shares by the Investors is not contingent upon any other event or condition, including but not limited to the effectiveness of the Registration Statement (as defined below) or the Company’s sale of any shares of Common Stock to the Investors to the Purchase Agreement. In connection with the Financing, the Company and the Investors also entered into a Registration Rights Agreement.

to the Financing, upon filing and effectiveness of a registration statement on Form S-1 (the “Registration Statement”) and provided other closing conditions are met, the Company shall have the right, but not the obligation, to direct the Investors to purchase shares of the Company’s Common Stock (the “Put Shares”) (i) in a minimum amount of not less than $20,000 and (ii) in a maximum amount of $1,000,000, provided that the number of Put Shares shall not exceed 300% of the average daily trading volume in the 10 trading days immediately preceding a Put Notice (as defined below). At any time, and from time to time during the term of the Purchase Agreement (the “Commitment Period”), the Company may deliver a notice to the Investors (the “Put Notice”) and shall deliver the Put Shares to Investors via DWAC within one trading day. The Purchase Price for the Put Shares is 85% of the lowest traded price (as reported by Bloomberg Finance L.P.) during the five trading days immediately following the date the Investors receive the Put Shares via DWAC associated with the applicable Put Notice (the “Valuation Period”). The closing of a Put Notice shall occur within one trading day following the end of the respective Valuation Period, whereby (i) the Investors shall deliver the investment amount to the Company by wire transfer of immediately available funds and (ii) the Investors shall return surplus Put Shares if the value of the Put Shares delivered to the Investors causes the Company to exceed the maximum commitment amount. The Company shall not deliver another Put Notice to the Investors within seven trading days of a prior Put Notice.

The right of the Company to issue and sell the Put Shares to the Investors is subject to the satisfaction of certain closing conditions, including, but not limited to, (i) an effective Registration Statement for resale by the Investors of the Put Shares and Commitment Shares, (ii) the accuracy of the Company’s representations and warranties, (iii) the Company’s performance of its obligations under the Purchase Agreement in all material respects, (iv) no suspension of trading or delisting of the Common Stock, (v) limitation of Investor’s beneficial ownership to no more than 9.99%, (vi) the Company’s maintaining its DWAC-eligible status, (vii) the Company maintaining a sufficient share reserve, and (viii) the minimum pricing for the Put Shares in the five trading days immediately preceding the respective Put Date exceeding $0.01.

The obligation of the Investors to purchase Common Stock from the Company will expire (the “Commitment Period”) on the earlier of (i) the date on which the Investors shall have purchased $10,000,000 value of shares of Common Stock from the Company to the Financing, (ii) January 31, 2021, or (iii) upon the Company’s provision of written notice to the Investors that it elects to terminate the Financing. Neither the Investors, nor any affiliate of the Investors acting on its behalf or to any understanding with it, will execute any short sales during the period from the date hereof to the end of the Commitment Period.

to the terms of the Registration Rights Agreement, the Company must file the Registration Statement which relates to the resale by the Investors of the Put Shares and Commitment Shares by March 16, 2018.

On the Closing Date, the Company reserved 64,725,377 shares of Common Stock from its authorized and unissued Common Stock to provide for all issuances of Common Stock under the Notes, the Warrants and the Financing.

The foregoing summary description of the terms of the documents (collectively, the “Transaction Documents”) to which the transactions described above were consummated on January 31, 2018, may not contain all information that is of interest to the reader. For further information regarding the terms of the Transaction Documents, reference is made to such Transaction Documents, which are filed hereto as Exhibits 10.1 – 10.9, and which are incorporated herein by this reference.

The information provided above in “Item 1.01 – Entry into a Material Definitive Agreement” of this Current Report on Form 8-K is incorporated by reference into this Item 3.02.

The issuance of the Commitment Shares, the Warrants and the issuance of the shares of the Company’s Common Stock upon exercise of the Warrants and the issuance of shares of Common Stock in connection with the Financing are exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), in reliance upon exemptions from the registration requirements of the Act in transactions not involving a public offering, including, but not limited to the exemption provided to Rule 506(b) of Regulation D, as promulgated by the Securities and Exchange Commission under the Act for offers and sales of restricted securities in a private, non-public transaction to accredited investors, as defined in Rule 501 of Regulation D.

Item 8.01Other Events.

The Company incorporates by reference herein the Press Release (attached as Exhibit 99.1) announcing the closing of the transactions described above.

Item 9.01Financing Statements and Exhibits.

(d) Exhibits

MEDIZONE INTERNATIONAL INC Exhibit
EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1     SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”),…
To view the full exhibit click here

About MEDIZONE INTERNATIONAL, INC. (OTCMKTS:MZEI)

Medizone International, Inc. is engaged in designing, manufacturing and selling a system using ozone in the disinfection of surgical and other medical treatment facilities and in other applications. The Company’s AsepticSure is an ozone-based technology, which is used for the purpose of decontaminating and disinfecting hospital surgical suites, emergency rooms, intensive care units and other enclosed spaces, such as gym locker rooms, laboratories and veterinary clinics. In the AsepticSure system, oxygen atoms are misted into the environment with a hydrogen peroxide vapor and the system’s formula creates Trioxidane. The Company is developing a variant of AsepticSure for governmental use with bio-terrorism countermeasures. AsepticSure has completed safety and preliminary operational trials. During the tests, AsepticSure has demonstrated a turnaround time of approximately 90 minutes for disinfection and reoccupation of the hospital rooms.